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Elevated antibody titres against certain Epstein–Barr virus (EBV)
antigens have been found in individuals several years before
presentation of Hodgkin’s disease (HD) (Mueller et al, 1989), and
in a majority of HD patients at diagnosis (Merk et al, 1992).
However, a positive association between EBV antibodies and the
presence of EBV in tumour cells has not been reported (Levine et
al, 1994; Enblad et al, 1997). Results of recent studies show the
presence of monoclonal EBV in about 30–70% of biopsies from
patients with HD (Herbst et al, 1991; Lauritzen et al, 1994), and
EBV has been suggested to play a role in the pathogenesis of HD.
EBV-positive (EBV+) Hodgkin (H) and Reed–Sternberg (RS)
cells express a restricted set of EBV gene products including latent
membrane protein 1 (LMP-1) and EBV encoded RNA (EBER)
(Lauritzen et al, 1994). LMP-1 is immunogenic and elicits a
cellular immune response in immunocompetent individuals
(Khanna et al, 1998; Murray et al, 1988). Although patients with
HD usually exhibit a variable HLA class I-restricted response to
EBV-derived antigens in peripheral blood lymphocytes, a marked
impairment of this response within the tumours has been detected
in patients with EBV+ HD tumours (Frisan et al, 1996). Of interest
in this context is the observation that, in addition to oncogenic
properties (Wang et al, 1985), LMP-1 also induces interleukin
(IL)-10 production in Burkitt lymphoma cell lines (Nakagomi et
al, 1994) and that IL-10 displays profound immunoregulatory
properties and may induce a long-term antigen-specific anergic
state in human CD4+ T-cells (Groux et al, 1996). It is also evident
that significantly more cases with IL-10-expressing tumour cells
are seen in LMP-1+ as compared to LMP-1-negative HD tumours
(Herbst et al, 1996). Thus, LMP-1 may also contribute to the local
inhibition of cellular immune responses observed in EBV-positive
HD tumours. These observations suggest that EBV+ HD could be
associated with a less favourable prognosis compared with EBV-
negative HD.
In vitro, LMP-1 induces up-regulation of CD54 (intercellular
adhesion molecule-1, ICAM-1) in HD cell lines (Knecht et al,
1996), but at present no increased expression of CD54 in EBV+
tumours has been reported (Kanavaros et al, 1993; Sandvej et al,
1993). To date, documentation on HD tumour cell association with
EBV and its possible correlation with prognosis is limited and
partly conflicting (Vestlev et al, 1992; Morente et al, 1997).
Here we have investigated the presence of EBV in HD tumour
cells in relation to EBV antibody titres, blood lymphocyte
function, soluble immunological factors, clinical chemistry and
prognosis in a well-characterized, previously untreated cohort of
patients with HD.
PATIENTS, MATERIALS AND METHODS
Patients and biopsies (Table 1)
Ninety-five patients, diagnosed during 1974–1991 in Stockholm as
having HD, were included in the study, since they had previously
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serum markers (Björkholm et al, 1978; Tullgren et al, 1991;
Grimfors et al, 1992; Merk et al, 1992; Axdorph et al, 1995). Three
patients were discordant with regard to LMP-1 and EBER expres-
sion and were excluded from further analysis; thus 92 patients
remained. The median age at diagnosis was 36 years (range 14–77
years), and the median follow-up time was 145 months (range
60–257 months) for surviving patients. The histopathology and the
immunophenotyping of all biopsies were reviewed (AP) and, when
necessary, complementary immunostainings for CD15, CD30,
CD20 and, in addition, LN-1, CD79a, CD3, UCHL-1 and EMA
were performed to confirm the diagnosis. The REAL classification
(Harris, 1995) was applied including the division of nodular
sclerosis (NS) according to the British National Lymphoma
Investigation (MacLennan et al, 1989). There were 59 patients with
NS and 33 patients with mixed cellularity (MC). Only one patient
with initial lymphocyte depletion was included, this patient was
reclassified to NS2. No cases of lymphocyte predominance were
included in the study. The extent of disease was evaluated
according to Ann Arbor staging classification (Carbone et al,
1971). Bulky disease was defined as a mediastinal mass with a
diameter exceeding one-third of the maximal mediastinal width or
any tumour manifestation with a diameter of >10 cm. Complete
remission (CR) corresponded to complete regression of all palpable
or histologically documented tumours and resolution of all
radiographic and biochemical abnormalities due to HD for a
minimum of 3 months.
Therapy
Patients with limited disease were treated with radiotherapy, and
patients in advanced stages were given chemotherapy, mainly
6–8 courses of MOPP (mechlurethamine, vincerstine sulphate,
procarbazine hydrochloride and premissive) or MOPP/ABVD
(doxorubicin, bleomycin, vinblastine and dacarbazine), for details
see Björkholm et al (1977, 1995). All clinical and immunological
studies were approved by the Ethics Committee at Karolinska
Institute Institutet and all patients gave informed consent.
LMP-1 immunostaining
After deparaffination and rehydration, standardized antigen
retrieval was performed using microwave irradiation (Kaczorowski
et al, 1994), and the slides were blocked with 5% BSA (bovine
serum albumin) for 30 min. Incubation with primary antibody
(mouse anti-EBV, LMP, CS 1–4; Dako A/S, Denmark) diluted in
1:40 was performed at room temperature for 1 h, followed by wash-
ings and detection of bound mouse immunoglobulin (Ig) by a
double APAAP (alkaline phosphatase-anti-alkaline phosphatase)
incubation (Cordell et al, 1984). The immunoreaction was visual-
ized by detection of bound APAAP with alkaline phosphatase
substrate kit I (Vector Red, Vector Laboratories, Inc., USA). Two
EBV-positive index cases and B-958 cell line cytospins were used
as positive controls for each batch of immunostaining. The case
was considered LMP-1 or EBER-positive if any HRS cell showed a
distinct membrane and/or cytoplasmic reaction.
EBER in situ hybridization
In situ hybridization (ISH) was performed with FITC (fluorescein
isothiocyanate)-labelled EBER probes (Dako, Glostrup, Denmark)
on paraffin sections. The sections were hybridized for 2 h at 37°C in
a solution with 30% formamid containing FITC-labelled probes
after dewaxing, rehydration and proteinase K (10 mg ml–1 ´ 20 min)
digestion. For detection of the bound FITC-labelled probe, a mono-
clonal FITC-specific antibody and a double APAAP procedure were
sequentially applied after washings and bound APAAP development
with BCIP/NBT (5-bromo-4-chloro-3-indolyl phosphate/nitro blue
tetrazolium). EBER+ cells were recognized by a dark blue nucleus.
Parallel hybridization of a section from an EBV+ case was used as a
positive control, and substitution of the probe with probe diluting
solution was used as a specificity control (Wu et al, 1991).
Sera
Before institution of therapy, serum samples were collected and
stored at –70°C until use.
Blood lymphocyte stimulation
Peripheral blood lymphocytes (PBL) were assayed for sponta-
neous and concanavallin A (Con A) induced DNA synthesis as
previously described (Tullgren et al, 1991). Patients with an
increased spontaneous (> mean of controls + 1 s.d.) and a
decreased Con A (< mean of controls –1 s.d.) induced PBL DNA
synthesis were defined to have an abnormal lymphocyte function.
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Table 1 Tumour EBV-status and clinical characteristics
Patient category EBV+ EBV– P-value
All patients 30 62
Sex
Male 20 33 NS
Female 10 29
Age
Years < 50 21 50 NS
Years ³ 50 9 12
Stagea
I9 1 4
II 7 23 NS
III 9 9
IV 5 16
B-symptoms
Yes 10 28 NS
No 20 34
Bulky status
Bulky 5 17 NS
Non-bulky 25 45
Histopathology
NS 1 6 28
NS 2 5 20 0.001
MC 19 14
Complete remission
Yes 28 54 NS
No 2 8
Relapse
Yes 8 19 NS
No 20 35
Prognosis
Deceased 10 21 NS
Survivors 20 41
Fourfold table, Fischer’s exact test. aEight-fold table, StatXact. NS = not
statistically significant.
}
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Serum factors
Serum levels of sCD54 were determined by the sandwich
immunoassay-method (Cellfree® ICAM-1 test kit, T-cell
Diagnostics). Samples were assayed in duplicate, and mean values
were calculated in compliance with the manufacturer’s instruction,
according to which the mean level in 66 healthy blood donors was
304 ng ml–1 with an upper limit of 460 ng ml–1 (mean + 2 s.d.).
sCD4 (Cellfree CD4, T-cell Sciences), sCD8 (Cellfree T8, T-cell
Sciences), sCD25 (Cellfree IL-2R test kit, T-cell Diagnostics) and
sCD30 (Dako CD30 [Ki-1 Antigen] enzyme-linked immuno-
sorbent assay (ELISA) were determined in similar ways by sand-
wich immunoassay methods.
b2-Microglobulin (b2-MG) was analysed by a competitive
luminometric assay (LIA-mat® b2-Microglobulin, Cambridge
Life Sciences plc, UK). Thymidine-kinase (TK) was measured in a
radio-enzyme assay (Prolifigen® TK-REA, AB Sangtec Medical).
Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP),
haemoglobin, white blood cell (WBC) counts, platelets, serum oroso-
mucoid, haptoglobin, albumin, IgG, IgA, IgM and lactate dehydroge-
nase (LDH) were determined according to standard methods.
Serum EBV antibodies
IgG antibodies to viral capsid antigen (VCA) and to early antigen
diffuse (EA-D) and early antigen restricted (EA-R) were detected
by indirect immunofluorescence according to Henle et al (1974).
Antibodies to Epstein–Barr nuclear antigen (EBNA) were
measured by anticomplement indirect immunofluoroscence
staining (ACIF) using Raji cells as described by Reedman and
Klein (1973). Detectable titres were defined as IgG VCA ³1:20,
IgG EA-D, IgG EA-R and EBNA ³ 1:5 (Enblad et al, 1997).
Statistical methods
Statistica version 4.1 program was used. Significance of differ-
ences between groups was tested by Mann–Whitney U-test.
Fischer’s exact test was used in fourfold tables (Armitage and
Berry, 1987) and StatXact was used in eightfold tables (Mehta et
al, 1984). In analyses regarding geometric mean titres (GMT), the
titres were regarded as approximately logarithmic-normally
distributed, why the titres were logarithmically transformed. These
mean values were tested by Student’s t-test. Survival analyses
were performed by Kaplan–Meier curves and the log-rank test.
Table 2a Tumour EBV-status and serum variables, all patients (n = 92)
Variable EBV+ EBV– P-value
(median, range) (median, range)
ESR (mm h–1) 21 (2–130) 38 (6–146) NS
CRP (mg l–1) 9.5 (5–123) 22 (5–164) NS
Hb (g l–1) 134 (90–157) 126 (83–154) NS
WBC count (109 l–1) 6.9 (3.2–19.7) 9.4 (1.9–25.7) 0.01
Eosinophil count (109 l–1) 0.15 (0–0.44) 0.17 (0–3.00) NS
Lymphocyte count (109 l–1) 1.18 (0.49–2.40) 1.08 (0.42–3.13) NS
Platelets (109 l–1) 299 (124–842) 322 (64–705) NS
IgG (g l–1) 12.8 (9.0–19.6) 13.0 (3.6–27.7) NS
sCD4 (U ml–1) 36 (10–114) 30 (16–92) NS
sCD8 (U ml–1) 355 (210–1260) 380 (27–4400) NS
sCD25 (U ml–1) 2225 (537–5132) 1987 (317–6177) NS
sCD30 (U ml–1) 33 (6–244) 55 (8–1124) NS (P = 0.056)
sCD54 (ng ml–1) 681 (145–1477) 528 (110–1560) 0.02
LDH (mkat l–1) 7.2 (0.1–12.8) 7.4 (3.7–16.4) NS
Mann–Whitney U-test. NS = not statistically significant.
Table 2b Tumour EBV-status and serum variables, patients with mixed cellularity histopathology (n = 33)
EBV+ EBV– P-value
(median, range) (median, range)
ESR (mm h–1) 16 (2–130) 30 (9–146) NS (P = 0.09)
CRP (mg l–1) 7 (5–106) 7 (5–147) NS
Hb (g l–1) 137 (90–157) 126 (90–154) NS
WBC count (109 l–1) 6.6 (3.5–19.2) 9.8 (6.9–17.2) 0.001
Eosinophil count (109 l–1) 0.12 (0–0.43) 0.37 (0–3.00) 0.01
Lymphocyte count (109 l–1) 1.13 (0.49–2.40) 1.37 (0.60–3.13) NS
Platelets (109 l–1) 293 (124–599) 312 (187–705) NS
IgG (g l–1) 12.4 (9.3–19.6) 15.6 (10.5–19.6) 0.02
sCD4 (U ml–1) 42 (10–114) 40 (16–92) NS
sCD8 (U ml–1) 430 (210–870) 410 (190–1360) NS
sCD25 (U ml–1) 2225 (749–4780) 1987 (687–5317) NS
sCD30 (U ml–1) 26 (6–79) 130 (8–683) 0.01
sCD54 (ng ml–1) 672 (145–1210) 498 (150–935) NS (P = 0.09)
LDH (mkat l–1) 7.0 (4.5–9.6) 8.8 (6–16.4) 0.01Tumour EBV status in Hodgkin’s disease 1185
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Overall survival was defined as the time from diagnosis to death of
any cause. Cause-specific survival was defined as the time from
diagnosis to death from HD or death related to HD (cardiovascular
second malignancy). Observations were censored by end of
follow-up or death without signs of HD.
RESULTS
The results of the various assays are presented in Tables 1–3. The
proportion of tumour EBV+ cases was significantly higher among
patients with MC (58%) histopathology as compared to the NS
subtype (18%; P < 0.001). The EBV+ and EBV– patients did not
differ significantly with regard to age, sex, stage, presence of bulky
disease or B-symptoms, remission rate or prognosis (Table 1).
Cause-specific or overall survival did not differ significantly
between EBV+ and EBV– patients (data not shown). No significant
differences were seen even when the analyses were restricted to the
MC-group (data not shown).
Total WBC counts were significantly lower among the EBV+
patients (P < 0.01, Table 2). No differences were found in total
lymphocyte or eosinophil WBC counts between the EBV+ and
EBV– patients. Levels of ESR and CRP were slightly lower in the
EBV+ group, but the difference did not reach statistical signifi-
cance (Table 2). No significant differences between the EBV+ and
EBV– patients were seen in serum orosomucoid, haptoglobin,
albumin, IgA and IgM, b2-MG and TK (data not shown), haemo-
globin, platelets, IgG and LDH (Table 2). Serum levels of IgG were
significantly lower in EBV+ than EBV– patients with subtype MC
(P < 0.02), as were the total (P < 0.001) and eosinophil (P < 0.01)
WBC counts and LDH (P < 0.01, Table 2).
The levels of sCD54 (sICAM-1) were significantly higher in the
EBV+ group (P < 0.02, Table 2). Levels of sCD30 (Ki-1) had a
tendency to be lower among the EBV+ patients, but the difference
did not reach statistical significance (P = 0.056, Table 2). When
this analysis was restricted to the MC-group, the levels of sCD30
were significantly lower in the EBV+ group (P < 0.01, Table 2).
No correlation between spontaneous blood lymphocyte DNA
synthesis or Con A induced blood lymphocyte DNA synthesis and
EBV-status of the patients was seen (data not shown). Thus,
lymphocyte abnormalities did not differ significantly between
EBV+ and EBV– patients (data not shown).
EBV antibodies (IgG VCA and EBNA titres) were detectable
in all of the 47 tested patients as evidence of a previous EBV
infection. Thirty-two patients with detectable IgG VCA (68%) had
EBV– biopsies. IgG VCA, IgG EA-D and EBNA titres did not
differ between patients with EBV+ and negative biopsies respec-
tively. However, significantly higher IgG EA-R titres were seen in
patients with EBV+ biopsies (P < 0.02, Table 3).
DISCUSSION
In this series of patients with HD, the proportion of EBV+ tumour
biopsies was 33%, with the majority (63%) diagnosed as MC
cases, which confirms previous findings (Herbst et al, 1991;
Pallesen et al, 1991; Pinkus et al, 1994; Enblad et al, 1997). This is
the first report to describe an association between a positive
tumour EBV status and increased sCD54 levels, elevated titres of
EA-R and a decreased WBC count in untreated HD. The increased
concentration of sCD54 in EBV+ patients may reflect the in vitro
finding that LMP-1 induces B-cell expression of CD54 (Wang et
al, 1988), which is the ligand for lymphocyte function-associated
antigen 1 (LFA-1) (Marlin and Springer, 1987). ICAM-1/LFA-1
regulates cell–stromal and cell–cell interactions such as leucocyte
adhesion (Makgoba et al, 1988a), mitogen-induced T-cell prolifer-
ation (Dougherty et al, 1988) and T-cell-mediated cytotoxicity
(Makgoba et al, 1988b). Furthermore, the CD30 ligand (CD30L),
a member of the tumour necrosis factor/nerve growth factor
(TNF/NGF) superfamily is known to up-regulate CD54 expression
by CD30+ cultured HRS cells, and to increase shedding of
surface-bound CD54 (Gruss et al, 1996). Pizzolo et al (1993) have
also reported that an increased expression of CD54 in HD tissue
was associated with high levels of serum sCD54, and with more
advanced clinical stage and the presence of constitutional symp-
toms and bulky disease. In a previous study, elevated sCD54
values were observed in patients with high age, advanced disease,
constitutional symptoms, lymphocytic depletion histopathology,
decreased remission rate and 5-year survival and abnormal
lymphocyte function (Axdorph et al, 1995). In contrast, other
authors did not find any difference in expression of CD54 between
LMP-1+ and LMP-1– tumour biopsies from HD patients.
However, the numbers of patients included in these studies were
quite limited (Sandvej et al, 1992; Kanavaros et al, 1993). Our
results showed EBV+ patients to have significantly higher levels
of sCD54 (P < 0.02) suggesting that indeed there is an association
between sCD54 and LMP-1 in HD tumours.
CD30 is a member of the TNF/NGF receptor superfamily
usually expressed on activated lymphocytes. A correlation between
the expression of LMP-1 and the detection of CD30 in HRS cells
has been suggested (Kanavaros et al, 1993). The CD30 antigen has
also been considered as a marker for HRS cells (Gruss and
Hermann, 1996). Moreover, the soluble form of CD30 (sCD30) has
been shown to be an indicator of disease activity and a predictor of
prognosis (Nadali et al, 1994), which is in good agreement with our
own unpublished observations. The CD30L is expressed on acti-
vated T-cells and has the ability to induce apoptosis in several
CD30+ cell lines (Younes et al, 1997). Thus, the increase in sCD30
can decrease the availability of CD30L on peripheral blood effector
lymphocytes. This blocking of CD30L apoptosis-inducing activity
may in turn impair immunosurveillance and contribute to the poor
prognosis observed in patients with elevated sCD30 levels (Younes
et al, 1997). In the present study, no strong correlation between
tumour EBV status and sCD30 levels was observed; EBV+ patients
with MC histopathology status had significantly lower sCD30
values (P < 0.01) than the corresponding EBV– group. In addition,
Table 3 Tumour EBV-status and EBV antibody titres (geometric mean)
EBV+ EBV– P-value
IgG VCA n = 15 n = 32
485.1 406.1
(255.5–920.0) (268.6–613.9) NS
EBNA n = 14 n = 27
51.2 63.5
(20.3–129.6) (34.1–118.1) NS
IgG EA-D n = 10 n = 22
13.2 11.7
(8.2–21.2) (8.4–16.2) NS
IgG EA-R n = 9 n = 23
29.4 12.7
(10.3–83.8) (10.7–15.1) 0.02
Student’s t-test, 95% confidence interval. NS = not statistically significant.cause-specific and overall survival was the same in these two
patient groups respectively.
As previously shown, increased spontaneous and decreased Con
A induced blood lymphocyte DNA synthesis both predict a poor
prognosis in HD (Björkholm et al, 1978; Wedelin et al, 1982;
Tullgren et al, 1991). In addition, increased levels of sCD8 was
associated with lymphocyte abnormalities and a dismal prognosis
(Grimfors et al, 1992). In this study no association was found
between tumour EBV status and spontaneous or Con A induced
blood lymphocyte DNA synthesis or sCD8 levels. Evidently, an
abnormal lymphocyte function can not directly be correlated to the
EBV-status of the tumour.
The findings of significantly lower total WBC and eosinophil
cell counts (P < 0.001 and P < 0.01 respectively) and IgG 
(P < 0.02), in the subgroup of EBV+ MC patients might possibly
indicate a down-modulation of the inflammatory response to the
tumour, which is supported by the tendency (P = 0.09), towards
lower ESR values in this patient group.
The relationship between the tumour EBV status of HD patients
and the serological responses has recently been analysed. No
correlation between serum antibody pattern and EBV tumour
status was found by Levine et al (1994) or Enblad et al (1997).
Previous reports have described EBV replication in RS cells as an
exceptional event (Brousset et al, 1993; Bibeau et al, 1994).
Pallesen et al (1991) showed that, in general, activation of EBV
early genes occurs only infrequently in RS cells. Enblad et al
(1997) found a significantly lower proportion of patients with
detectable titres of IgG EA-R in the tumour EBV+ patients in
comparison to EBV–, but in that study, no significant difference in
EA-R antibody titres was recorded between EBV+ and EBV–
patients. In the present study, IgG VCA, IgG EA-D and EBNA
titres did not differ between tumour EBV+ and EBV– patients,
while the EA-R antibody titre was significantly higher in the
EBV+ group (P < 0.02, Table 3), suggesting the presence of EBV
replication. The discrepancy, if any, between the results reported
by Enblad et al and the present series, may be due to differences in
the patient populations.
Few studies have related tumour EBV status to patient outcome.
In addition, our findings are in agreement with reports of Vestlev
et al (1992) and Enblad et al (1997), who found no difference in
progression-free or cause-specific survival respectively, between
EBV+ and EBV– patients, but disagree with the results reported
by Morente et al (1997), where patients with EBV+ biopsies had a
longer overall survival. However, there was a tendency to more
relapses among EBV– patients in our series.
In summary, in our patient series a higher proportion of EBV+
tumour biopsies was confirmed in patients with MC
histopathology. Despite the potential pathogenetic role of EBV in
HD, there was no association between tumour EBV status and
lymphocyte function or outcome. A potential causal relationship
between EBV tumour status and sCD54 and total WBC counts
needs to be further explored.
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